Home › Companies › CBIO

Crescent Biopharma

Market cap $507M 38.9M shares (10-Q, Nov 11, 2026) × $13.04 close Nov 17, 2026

Most recent annual filing: 2026-02-26

Catalyst timeline

7 trackedQuarter catalyst calendar →
  1. CR-001 + ADC combination trial2H 2026CR-001 + ADC combination trial, 2H 2026, notable
  2. CR-001 Ph1 topline1Q 2027CR-001 Ph1 topline, 1Q 2027, thesis-defining
  3. CR-003 / SKB105 Ph1 readout1Q 2027CR-003 / SKB105 Ph1 readout, 1Q 2027, material
  4. Portfolio corporate updatemid-2027Portfolio corporate update, mid-2027, routine
  5. CR-001 + Kelun-Biotech ADCs combination2H 2027CR-001 + Kelun-Biotech ADCs combination, 2H 2027, material
  6. CR-002 2 proof-of-concept Ph1 interim2H 2027CR-002 2 proof-of-concept Ph1 interim, 2H 2027, material
  7. CR-002 Ph1 start2H 2027CR-002 Ph1 start, 2H 2027, routine

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (10 active programs)

CR-001

SKB118
Protein Target: PD-1, VEGF

CR-003

SKB105
Protein Target: ITGB6
  • Undisclosed indication Phase 1 Phase 1/2 trial Sichuan Kelun-Biotech Biopharmaceutical

Capital (as filed)

Cash
$289M cash and cash equivalents · Sep 30, 2026 (10-Q)
Operating cash flow
−$26.9M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
As stated in coverage
$289M cash, runway second half of 2028 per the update of Nov 12, 2026 — the company's own words as read there, not the filed figure

Offering documents (4)

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.

Biotech Distilled coverage (9)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (9 calls)

Every verdict Biotech Distilled has published on Crescent Biopharma, oldest first — the full history, never a selection. How calls are scored: the track record.

  1. Buy core Crescent Bio (CBIO) - Scientific Deep Dive for CR-001, CR-003, and Pipeline Products High-conviction play on a validated PD-1/VEGF bispecific architecture (CR-001) with a pristine balance sheet bridging to the Q1 2027 ASCEND catalyst, positioned as a premier M&A target for Big Pharma facing patent cliffs.
  2. Buy core UPDATE: Crescent Biopharma (CBIO) - The Shelf Goes Up Six Months Early Scientific thesis and Fairmount anchor intact, but the ATM filing introduces a dilution tap that caps upside asymmetry on the pre-catalyst run-up leg; accumulation thesis maintained with wider expected variance.
  3. Watch UPDATE: Crescent Biopharma (CBIO) - The Dilution Tap Opens Management launched an aggressive marketed follow-on at a 15% discount to the original accumulation zone six months before catalyst, breaking the pre-catalyst compounding trade; waiting for pricing print and sponsor-participation tea leaves before re-entering.
  4. Buy core UPDATE: Crescent Biopharma (CBIO) - The Pricing Print Clears The dilution overhang priced at $14.50 with the market absorbing the deal without imploding, creating a 30-day underwriter defense window and a known ATM re-arming date, making the post-pricing entry at $14.50–$15.70 a materially better setup for the same Q1 2027 catalyst on an over-funded balance sheet.
  5. Buy core UPDATE: Crescent Biopharma (CBIO) - The Architect Wrote a Check Fairmount's $20M participation in the follow-on via the pre-funded tranche is an ambiguously positive sponsor signal — not a full-throated green flag but better than silence — leaving the post-pricing BUY thesis intact.
  6. Buy core UPDATE: Crescent Biopharma (CBIO) - The Combination Trial Is Live Greenshoe fully exercised confirming healthy demand, pro forma cash of $305M into 2H 2028, and the CR-001 + sac-TMT Phase 2 now enrolling expand the thesis from a single Q1 2027 binary to four dated readouts across five quarters on an over-funded balance sheet.
  7. Buy core UPDATE: Crescent Biopharma (CBIO) - The Third Program Clears the Gate FDA IND clearance for CR-002 (APOLLO trial) lands on schedule, closing a key watch-list item and moving CR-002's 2H 2027 readout from planned to cleared, while the $305M balance sheet funds APOLLO without new dilution pressure.
  8. Buy core UPDATE: Crescent Biopharma (CBIO) - The Big One Gets Smaller Execution remains on track with dose escalation complete and 125+ patients dosed, but the Q1 2027 ASCEND efficacy readout is now confirmed as a 12-patient ORR snapshot — a noisier, smaller test than originally framed — making the mid-2027 combination data the more durable thesis test.
  9. Buy core UPDATE: Crescent Biopharma (CBIO) - The Tap Opened Into Strength Both open watch-list items resolved favorably — APOLLO dosed its first patient in Q4 as guided and the ATM was used opportunistically at ~$20/share (~40% above the July follow-on price) — confirming management is selling into strength rather than weakness ahead of the Q1 2027 ASCEND readout.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Timing, in the company's words (7 quotes from 4 filings)

Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.

Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.

Filings & releases (33)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from May 21, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

14 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)